Polistyrenosulfonian sodu: interakcje

Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. (etykieta leku Amiloryd, Przeciwwskazania)

…with: • type 2 diabetes with microalbuminuria, • serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions… (etykieta leku Eplerenon, Przeciwwskazania)

• GI Toxicity with Solid Oral Dosage Forms of Potassium Chloride : Concomitant use is not recommended. (etykieta leku Glikopironium, Interakcje z innymi lekami)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Information for patients Patients who receive spironolactone and hydrochlorothiazide tablets should be advised to avoid potassium supplements and foods containing high levels of potassium including salt substitutes. (etykieta leku Spironolakton + hydrochlorotiazyd, Środki ostrożności)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (etykieta leku Aliskiren, Ostrzeżenia i środki ostrożności)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes. (etykieta leku Amlodypina + benazepryl, Ostrzeżenia i środki ostrożności)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (etykieta leku Amlodypina + walsartan, Interakcje z innymi lekami)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (etykieta leku Benazepryl, Ostrzeżenia i środki ostrożności)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (etykieta leku Cyklosporyna, Interakcje z innymi lekami)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions ( 7.3 )]. (etykieta leku Enalapryl, Ostrzeżenia i środki ostrożności)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (etykieta leku Enalapryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (etykieta leku Enalaprylat, Interakcje z innymi lekami)

Monitor serum potassium levels; use potassium supplements if necessary. (etykieta leku Fludrokortyzon, Interakcje z innymi lekami)

Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia. (etykieta leku Fozynopryl, Interakcje z innymi lekami)

Drug Interactions Potassium supplements and potassium-sparing diuretics As noted above (“Derangements of Serum Electrolytes”), the net effect of fosinopril sodium and hydrochlorothiazide may be to elevate a patient’s serum potassium, to reduce it, or to leave it unchanged. (etykieta leku Fozynopryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Coadministration of AVALIDE with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe. (etykieta leku Irbesartan + hydrochlorotiazyd, Ostrzeżenia i środki ostrożności)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (etykieta leku Jodek potasu, Interakcje z innymi lekami)

Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etykieta leku Kandesartan, Interakcje z innymi lekami)

Co-administration of candesartan cilexetil and hydrochlorothiazide tablets with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. (etykieta leku Kandesartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. (etykieta leku Kaptopryl, Interakcje z innymi lekami)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Drug or Drug Class Effect Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer Bile acid sequestrants and ion exchange resins are known to decrease thyroid hormones absorption. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Decreased absorption of lithium and thyroxine have also been reported with co-administration of Sodium Polystyrene Sulfonate Powder, for Suspension. (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.1) ] . (etykieta leku Lizynopryl, Ostrzeżenia i środki ostrożności)

Use of lisinopril with potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. (etykieta leku Lizynopryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Potassium Supplements and Potassium-Sparing Diuretics: Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. (etykieta leku Moeksypryl, Interakcje z innymi lekami)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.3) ] . (etykieta leku Olmesartan, Ostrzeżenia i środki ostrożności)

Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and the concomitant use of agents such as potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes [see Drug Interactions (7.2) ] . (etykieta leku Peryndopryl, Ostrzeżenia i środki ostrożności)

Potassium-Sparing Diuretics As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium [see Warnings and Precautions (5.5)] . (etykieta leku Sakubitryl + walsartan, Interakcje z innymi lekami)

Cation-Donating Antacids The simultaneous oral administration of Sodium Polystyrene Sulfonate Powder, for Suspension with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis 7.3 Sorbitol Sorbitol may contribute to the risk of intestinal necrosis [ see Warnings and… (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (etykieta leku Spironolakton, Ostrzeżenia i środki ostrożności)

Hyperkalemia Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (etykieta leku Telmisartan, Ostrzeżenia i środki ostrożności)

Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. (etykieta leku Telmisartan + amlodypina, Ostrzeżenia i środki ostrożności)

Sodium Polystyrene Sulfonate (SPS): Separate administration by at least three hours ( 7.2 ). (etykieta leku Tenapanor, Interakcje z innymi lekami)

Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. (etykieta leku Trandolapryl, Interakcje z innymi lekami)

Sodium polystyrene sulfonate may be administered to enhance the excretion of excess potassium. (etykieta leku Triamteren, Ostrzeżenia i środki ostrożności)

Exchange resins, such as sodium polystyrene sulfonate, whether administered orally or rectally, reduce serum potassium levels by sodium replacement of the potassium; fluid retention may occur in some patients because of the increased sodium intake. (etykieta leku Triamteren + hydrochlorotiazyd, Interakcje z innymi lekami)

Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine ( 7.1 ) (etykieta leku Walsartan, Interakcje z innymi lekami)

…Serum Potassium: Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart… (etykieta leku Walsartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Cation-Donating Antacids: may reduce the resin’s potassium exchange capability and increase risk of systemic alkalosis ( 7.2 ). (etykieta leku Polistyrenosulfonian sodu, Interakcje z innymi lekami)

Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. (etykieta leku Benazepryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Supplemental potassium and/or spironolactone may prevent hypokalemia and metabolic alkalosis in these patients. (etykieta leku Bumetanid, Ostrzeżenia)

Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (etykieta leku Dobutamina, Interakcje z innymi lekami)

Drug interactions may occur when anticholinergics are used with the following medications: antacids, antidiarrheals (adsorbent), other anticholinergics, antimyasthenics, cyclopropane, haloperidol, ketoconazole, metoclopramide, opioid (narcotic) analgesics, and potassium chloride. (etykieta leku Hioscyjamina, Interakcje z innymi lekami)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (etykieta leku Milrinon, Interakcje z innymi lekami)